Biotricity Set to Reveal FY 2025 Financial Performance Soon
Biotricity to Discuss Impressive Financial Performance
The company aims to share advancements in margins and operational efficiency.
Upcoming Event Details
Biotricity Inc. (OTCQB: BTCY), a pioneering Technology-as-a-Service (TaaS) firm, is excited to announce its upcoming call to present the second quarter fiscal year 2025 financial results. Set to be hosted on November 15, 2024, this event promises to be significant as the company showcases its exceptional financial achievements and progress towards a positive adjusted EBITDA.
Event Specifics
The event will feature remarks from Biotricity’s esteemed leaders, including Dr. Waqaas Al-Siddiq, the Founder and CEO, and John Ayanoglou, the Chief Financial Officer. Following their presentations, a Q&A session will provide investors the opportunity to raise their questions.
Details for the event are as follows:
Date: Friday, November 15, 2024
Time: 4:30 PM ET (1:30 PM PT)
Toll-Free Number: 877-269-7751
International Dial-In: 1-201-389-0908
Webcast Link: available on the official website.
Accessing the Webcast
Investors will find it easy to access the webcast, which can be joined 15 minutes prior to the start time. An operator will facilitate the registration of participants.
Replay Information
A replay will be made available approximately three hours post-event via the Investors section on Biotricity’s website. Should you wish to listen to the call at a later time, here are the options:
Toll-Free Replay Number: 844-512-2921
International Replay Number: 1-412-317-6671
Replay Access ID: 13750135
Available Until: November 29, 2024, at 11:59 PM ET.
About Biotricity Inc.
With a focus on enhancing the future of healthcare, Biotricity is leading the charge in remote monitoring and chronic care management. The company's innovative solutions have been embraced by both medical professionals and patients, who place their trust in Biotricity's standards of preventive care. The expertise extends across a wide array of diagnostic and post-diagnostic services, catering to chronic health conditions.
The firm is continually dedicated to developing comprehensive health monitoring solutions aimed at both the medical and consumer sectors. Biotricity is excited about its pivotal role in redefining health care delivery via advanced technology.
Frequently Asked Questions
What is the purpose of the upcoming call hosted by Biotricity?
The call will discuss Biotricity's financial performance and positive adjustments in their earnings during the second quarter of fiscal year 2025.
When is the call scheduled to take place?
The call is set for November 15, 2024, at 4:30 PM ET.
Who will be speaking during the call?
The event will feature presentations from Dr. Waqaas Al-Siddiq, the Founder and CEO, and CFO John Ayanoglou.
How can investors access the call?
Investors can join the call by dialing the toll-free number or the international number provided before the call starts.
Is there a way to listen to the call after it is finished?
Yes, a replay will be available approximately three hours after the live event on Biotricity's website under the Investors section.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.